Merrill reiterates Martek at sell

Martek Biosciences was reiterated by Merrill Lynch analyst David Munno at a sell rating as the company prepares to release its fourth quarter and fiscal year financial reports after the Dec. 13 close. Management could discuss the potential for food deals in 2006 that could boost stock in the near term, but with DHA for infant formula likely to go into brand extensions, Merrill Lynch said food revenues are not likely to exceed $5 million in 2006. Shares of the Columbia, Md., biotechnology company were down 4 cents, or 0.14%, at $28.17 on volume of 442,898 shares versus the three-month running average of 924,330 shares.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.